CARCINOGENIC POTENCY TESTS
\kˌɑːsɪnə͡ʊd͡ʒˈɛnɪk pˈə͡ʊtənsi tˈɛsts], \kˌɑːsɪnəʊdʒˈɛnɪk pˈəʊtənsi tˈɛsts], \k_ˌɑː_s_ɪ_n_əʊ_dʒ_ˈɛ_n_ɪ_k p_ˈəʊ_t_ə_n_s_i t_ˈɛ_s_t_s]\
Sort: Oldest first
-
Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.